Back to Archived News
Metabolon Awarded Additional Metabolomics Patent
Wednesday, June 11, 2008
Company Continues to Expand Intellectual Property Protection
Research Triangle Park, NC -- Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that the company has been awarded another metabolomics patent. The newly issued patent further expands the domain of previously issued patents to include multiple disease states related to nervous systems disorders including Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, depression and schizophrenia.
"Metabolon has assembled the most substantial IP portfolio in the metabolomics and small molecule diagnostics industries," said John Ryals, chief executive at Metabolon. "We have strategically built an IP estate comprised of trademarks, copyrights and patents, including broad metabolomics methods, data analysis and biomarker patents, and focused product patents that protect critical points along our value chain."
Metabolon’s patent portfolio is comprised of over 75 US and worldwide patents and patent applications, including many ground-breaking patents in the field of metabolomics. This includes Metabolon’s unique position as the exclusive license holder of the Daouk-Kristal patent family comprised of pioneering patent applications for the use of metabolomics in drug discovery, disease treatment and diagnosis, giving the company a strong competitive advantage in the marketplace.
"Building a solid IP portfolio is without question critical to any life science organization’s success," Metabolon’s Director of Research and Intellectual Property, Kay Lawton, Ph.D., commented. "In the rapidly growing field of metabolomics, we have been able to create a strong competitive position by obtaining many of the pioneering patents that will continue to drive Metabolon and the industry forward in small molecule biomarker identification and diagnostics."
Pending data analysis and software patents cover critical aspects of the company’s metabolomics platform, including collection and analysis of the massive amounts of data generated by metabolomics experiments. In addition, Metabolon has pending patents directed to small molecule biomarkers related to drug action, toxicity, carcinogens, aging and numerous other diseases and disorders.
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.
Back to Archived News